Eli Lilly (LLY) Retatrutide Shows 28.3% Average Weight Loss in Phase 3 Trial

Eli Lilly's experimental obesity drug retatrutide delivered an average 28.3% body-weight reduction over 80 weeks in the Phase 3 TRIUMPH-1 trial, a result that has helped lift LLY by nearly 9% in August and put the drugmaker at the center of the metabolic-drug rally. The efficacy reading approaches outcomes historically associated with bariatric surgery and outperforms current treatments: patients on Novo Nordisk's Wegovy typically lose about 14% after 72 weeks, while users of Lilly's Mounjaro average roughly 20% over a comparable period. The company said 45% of participants on the highest retatrutide dose lost at least 30% of their body weight, and 65% on that dose no longer met criteria for obesity. The same summary showed an average absolute reduction of about 70 pounds on the top dose, a figure Lilly executive Patrik Jönsson said the company had not previously seen at that magnitude. The candidate also showed benefit beyond weight management; in the TRIUMPH-4 study, patients with knee osteoarthritis reported substantial pain reduction. That breadth is a reason retatrutide is seen as a potential blockbuster rather than an incremental label expansion. The commercial backdrop is already large: Lilly's valuation stands at roughly $1.1 trillion, an all-time-high valuation for a pharmaceutical company, supported by Mounjaro's more than €27 billion in trailing twelve-month revenue and a market cap about five times Novo Nordisk's and more than four times AstraZeneca's. The stock's August advance reflects that optimism, but the premium leaves little room for error: a clinical setback, regulatory delay or reimbursement squeeze could quickly reset expectations.

The investment case does not rest solely on an experimental molecule. Mounjaro generated more than €27 billion in revenue over the previous twelve months, according to the company's investor-relations disclosure, and Lilly's second-quarter 2026 report showed revenue rising 48% year over year to $23 billion with EPS up from $6.30 to $7.94. Revenue beat analyst estimates by 11%, while EPS came in 5.3% ahead. That followed a first quarter in which revenue climbed 56% to $19.8 billion and net income jumped 168% to $7.4 billion, after full-year 2025 revenue had already expanded 45% to $65.2 billion. Management has repeatedly raised its outlook, moving 2026 guidance from an initial $80 billion–$83 billion range to $82 billion–$85 billion in May and then to $85 billion–$87 billion in August. Analysts currently model about 11% annual revenue growth, 16.6% earnings growth, EPS growth near 16.8% and a forecast return on equity close to 50% over the next three years, a slowdown from the company's historical average annual earnings growth of more than 35% but still robust for a group of this size. Price-prediction models see LLY trending from about $1,174 in August to roughly $1,365 by November and ending the year near $1,360–$1,377, with a shallow correction to about $1,220 by March 2027 before a later acceleration above $1,700 by July. The most aggressive scenario in those models places the stock near $1,962 in August 2027 with a peak above $2,073. The models also frame the early-2027 dip as a temporary correction rather than a trend reversal, with momentum expected to rebuild quickly. Access and reimbursement remain the major uncertainties around the launch, but the forecast assumes Lilly's execution continues through the rollout. For crypto-native readers, the August move resembles an altcoin rally more than a conventional pharma repricing, even though the catalyst here is clinical data rather than token supply mechanics.

Taken together, the trial readout and the earnings trajectory form a single narrative: clinical data create the ceiling, while commercial execution sets the floor. In our reading, the August guidance revision is the most load-bearing primary document because management embedded the obesity franchise's momentum into formal targets before retatrutide contributes sales. The unresolved question is valuation, not science. At roughly $1.1 trillion, LLY must sustain double-digit growth to justify its all-time-high valuation, and any reimbursement friction around next-generation obesity drugs would test that assumption. The disclosure trail for now points to a company growing revenue faster than most large-cap peers, with a pipeline it believes is in a class of its own. The August advance was not a token airdrop or an AI trading bot signal; it followed a Phase 3 readout and repeated upward guidance revisions.